Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03608631 · ClinicalTrials.gov registry record · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
A Phase 1 study of Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03608631 is a Phase 1 study of Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Adenocarcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 28 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03608631, a Phase 1 study of Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.
Conditions Studied
Interventions
- DRUG Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-01-27 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03608631
The ClinicalTrials.gov registry entry for NCT03608631 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (95% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA is the first listed.
NCT03608631 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03608631 about?
NCT03608631 is a clinical study titled "iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation". This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic...
What is the current status of trial NCT03608631?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2021-01-27. Estimated completion is 2027-04-30.
What conditions does trial NCT03608631 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, KRAS NP_004976.2:p.G12D.
What interventions are being tested in trial NCT03608631?
The interventions under investigation include: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA (DRUG).
Who is sponsoring clinical trial NCT03608631?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03608631 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
RECRUITING · Phase 1
Explore more on PlainTrial
Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
Metastatic Pancreatic Adenocarcinoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.